Company Logo

Company Logo

Dublin, Oct. 26, 2023 (GLOBE NEWSWIRE) -- In a significant development reported this month in JAMA Network Open, South Korean researchers have pointed out an increased risk of various new-onset autoimmune and autoinflammatory connective-tissue disorders post-COVID-19 infection. As the global medical and business communities strive to understand the implications of these findings, introduces the comprehensive database "Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) - Market Insights, Epidemiology and Market Forecast - 2032"

For entrepreneurs and business managers aiming to navigate the complexities of this rapidly emerging health concern, this database is an invaluable tool. It offers in-depth insights into Connective Tissue Diseases (CTDs), which are systemic autoimmune disorders targeting the body's connective tissues, such as rheumatoid arthritis, systemic lupus erythematosus, and Sjogren's syndrome, among others.

CTDs can lead to severe complications in the pulmonary system. Inflammation and scarring between the lung's air sacs and blood vessels, characteristics of Interstitial Lung Disease (ILD), are often a result of CTDs. When these two intersect, leading to CTD-ILD, patients may experience shortness of breath, coughing, and fatigue.

Given the seriousness of these complications and the challenges associated with diagnosing CTD-ILD, the gold standard remains high-resolution CT (HRCT). The database sheds light on the diagnostic criteria set forth by renowned organisations, including the British Thoracic Society, American Thoracic Society, and the Japanese Respiratory Society.

Moreover, country-specific data variations, which can play a pivotal role in global market decisions, are thoroughly documented within the resource.

Treatment paradigms for CTD-ILD are intricate. Factors like the specific CTD diagnosis, time since diagnosis, ILD severity, course of the illness, and individual patient parameters play a determining role. Patients diagnosed with CTD-ILD usually undergo immunotherapies and other medications to decelerate the progression of their ailment. The database offers a meticulous overview of these treatment regimens, encompassing corticosteroids, immunosuppressants, antifibrotic medicines, and molecular-targeting biologics.

In light of the recent JAMA Network Open article, which emphasises the repercussions of COVID-19 on the onset of connective tissue disorders, the importance of such a comprehensive database cannot be understated. Business leaders, particularly in the pharmaceutical and medical industries, need access to such consolidated, in-depth information to make informed decisions.

The "CTD-ILD - Market Insights, Epidemiology and Market Forecast - 2032" database is primed to cater to these precise needs. With the potential business landscape around CTD-ILD evolving rapidly, timely, accurate, and actionable insights can make the difference between seizing an opportunity and missing it.

For business entrepreneurs and managers, this database isn't just a compilation of facts. It's a key to unlocking potential market avenues, understanding emerging patterns, and staying ahead in an ever-evolving industry landscape. As we learn more about the long-term impacts of global phenomena like COVID-19, tools such as these are not just beneficial but essential for forward-thinking businesses.

For further details, please visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Source link